Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-21
    E.g., 2018-06-21


19304 items
7:02 PM, Jun 08, 2018  |  BioCentury | Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together, data...
6:43 PM, Jun 08, 2018  |  BioCentury | Product Development

Past not prologue

Loxo Oncology Inc.’s two-year streak of stunning data at ASCO appears to be the result of good decisions on the back of a healthy dose of luck. But it will be a tall order to...
8:32 AM, Jun 08, 2018  |  BioCentury | Finance

Pfizer plugs back in

While Pfizer Inc. (NYSE:PFE) retreated from neuroscience R&D in January, the pharma hasn’t cut the cord yet. Ramped up allocations to neuroscience out of its latest $600 million venture investment give Pfizer the ability to...
7:58 AM, Jun 08, 2018  |  BioCentury | Finance

Nimbus looks inward

Nimbus plans to use a $65 million financing it raised on Tuesday to take programs deeper in development, refining its founding strategy of partnering its compounds early on. Existing investor Atlas Venture led the round,...
5:24 PM, Jun 05, 2018  |  BioCentury | Product Development

Second (Ex)act

Armed with Phase II data for its second DNA methylation test, Exact Sciences Corp. expects a repeat performance of the rapid launch trajectory its Cologuard colorectal cancer screening assay has enjoyed. Cologuard beat expectations for...
10:25 AM, Jun 02, 2018  |  BioCentury | Politics, Policy & Law

Getting flatter

Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, brought the center’s entire staff of about 5,000 people together in the agency’s Great Room on June 1 for a town hall meeting to...
10:50 PM, Jun 01, 2018  |  BioCentury | Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
10:29 PM, Jun 01, 2018  |  BioCentury | Strategy

Partnering on a mission

With a $260 million war chest and a banner roster of execs, advisors and deals, Brii Biosciences is pushing an agenda to bring infectious diseases to the forefront of innovation in China. Its top priority...
6:30 PM, Jun 01, 2018  |  BioCentury | Product Development

ASCO: Pushing precision’s evolution

As the list of targeted therapies gaining approval grows, encompassing an increasingly broad spectrum of cancers, this year’s ASCO meeting aims to educate clinicians about how to determine which drugs are best in class for...
3:11 PM, Jun 01, 2018  |  BioCentury | Emerging Company Profile

Scratching the surface

Oppilotech Ltd. is using computational modeling to develop first-in-class compounds that can permeate the lipopolysaccharide layer of the outer cell membrane of Gram-negative bacteria to potentiate existing antibiotics. Marketed polymyxins are used to disrupt the lipopolysaccharide...